Mrinal M. Gounder

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S1 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Figure S5 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Figure S2 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Data from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Figure S4 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Table S2 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Figure S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Table S1 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Supplementary Table S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

  2026-06-17

• Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials

  Cancer Medicine · 2026-06-01

• A phase Ib/II study of mirdametinib in combination with palbociclib in patients with advanced dedifferentiated liposarcoma.

  Journal of Clinical Oncology · 2026-05-28

• Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

  Journal of Clinical Oncology · 2026-05-28

• Impact of concomitant medications on immune checkpoint inhibitor outcomes in sarcoma.

  Journal of Clinical Oncology · 2026-05-27

• First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).

  Journal of Clinical Oncology · 2026-05-27

• RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.

  Journal of Clinical Oncology · 2026-05-27

• Secondary genomic alterations and clinical outcomes in myxoid liposarcoma: A multi-institutional analysis.

  Journal of Clinical Oncology · 2026-05-27

• Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma

  Journal for ImmunoTherapy of Cancer · 2026-05-01

• Reply to: In DeFi-ance of “More Is Better”: Questioning Long-Term Nirogacestat Use in Desmoid Tumors

  Journal of Clinical Oncology · 2026-04-24

• Abstract CT295: Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors

  Cancer Research · 2026-04-17

• Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study

  Nature Communications · 2026-03-25 · 1 citations